Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases
As our understanding of immune mediated chronic inflammatory diseases (IMIDs) grows, it becomes more and more clear that these conditions result from the convergence of a multitude of pathogenic mechanisms whose relative individual contribution is differe
- PDF / 2,766,514 Bytes
- 206 Pages / 439.42 x 683.15 pts Page_size
- 47 Downloads / 183 Views
Paola Mina-Osorio Editor
Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases
Progress in Inflammation Research Series Editors
Michael J. Parnham Fraunhofer IME & Goethe University Frankfurt, Germany Achim Schmidtko Goethe University Frankfurt, Germany
More information about this series at http://www.springer.com/series/4983
Paola Mina-Osorio Editor
Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases
Editor Paola Mina-Osorio US Medical Division Eli Lilly & Company New York, NY USA Series Editors Michael J. Parnham Fraunhofer IME & Goethe University Frankfurt Germany
Achim Schmidtko Goethe University Frankfurt Germany
Progress in Inflammation Research ISBN 978-3-319-42251-0 ISBN 978-3-319-42252-7 (eBook) DOI 10.1007/978-3-319-42252-7 Library of Congress Control Number: 2016961232 © Springer International Publishing Switzerland 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
As our understanding of immune-mediated chronic inflammatory diseases (IMIDs) grows, it becomes more and more clear that these conditions result from the convergence of a multitude of pathogenic mechanisms whose relative individual contribution is different in different patient subsets. As a result, patients suffering from these diseases present with diverse phenotypes that we artificially pool together for the investigation of therapeutic efficacy. Basic researchers have concentrated their efforts in modeling complex human disease in vitro and in animals. Even though this practice has indeed led to important discoveries trailed by the development of breakthrough medicines that curve the inflammatory cascade responsible for some of the most important signs and symptoms of IMIDs, none of these med
Data Loading...
